Nothing like a long weekend to kick back and recharge. And it was a nice, quiet long weekend from where we sit. No primaries, not a lot of interesting sports (the cupcake dunk at NBA all-star weekend notwithstanding), only a small handful of multi-billion dollar bank write-downs. Oh, and apparently enjoying the time off so much, Fidel Castro decided to retire. What are the odds he moves to Florida? Elsewhere ... - '60 Minutes' goes after Bayer's Trasylol and FDA (hat tip Pharmagossip)
- GSK licensed a preclinical antibody targeting interleukin-6 from Eusa Pharma, for a total consideration of up to $44 million in upfronts and milestones (half of which will go to Eusa partner Vaccinex).
- Bayer abandoned a late-stage Nexavar/chemotherapy combo trial after a monitoring board suggested the cocktail wasn't prolonging survival in patients with non-small cell lung cancer.
- For Sale: yet another UK biotech company. Two marketed products. Endocrine specialist. $50mm ONO.
- A shake-up at Edwards Life Sciences sees some long-standing executives leaving the device firm.
- Time for consolidation in the pharmaceutical supply sector? The Boston Globe finds a few people who think so.
photo from flickr user chadh used under a creative commons license
No comments:
Post a Comment